Objective: To investigate the relationship between the etiology, laboratory findings and prognosis of secondary HPS, so as to enhance the understanding of the secondary HPS and the related factors affecting prognosis, reduce the misdiagnosis and to understand the factors that affect the prognosis.
Methods: The etiology, laboratory findings and prognosis of 61 patients with secondary HPS were analyzed retrospectively.
Results: Univariate analysis showed that TG, FIB, SF, ANC, ALB, TBIL, ALT, LDH were significantly different between the 2 groups of the patients with secondary HPS. Multiariate factor analysis showed that the LDH and the etiology affected the prognosis of the patients with secondary HPS. The prognosis of the patients with elevated LDH, viral infection, especially EB virus infection, tumor and unknown causes might be poor.
Conclusions: The etiology and clinical characteristics of prognosis are diverse. The cause needs to be identified as soon as possible. The prognosis should be judged according to LDH and other indicators. Then, targeted therapy should be used to control the disease in the short time.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7534/j.issn.1009-2137.2016.02.051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hantavirus Pulmonary Syndrome in Northwestern Argentina: Seroprevalence in rodents of Jujuy province and first seropositive record for Euryoryzomys legatus.
Acta Trop
December 2024
Laboratorio de Ecología Evolutiva y Biogeografía (LEEB) - Instituto de Ecorregiones Andinas-Consejo Nacional de Investigaciones Científicas y Técnicas(CONICET) - Universidad Nacional de Jujuy (UNJu), Gorriti 237, San Salvador de Jujuy, Jujuy, Argentina. Electronic address:
Hantavirus Pulmonary Syndrome (HPS) is a Pan-American emerging infectious disease with a high mortality rate caused by rodent-borne viruses of the genus Orthohantavirus. In Argentina, almost half of the HPS infections occur in the northwestern endemic region. In this study, we evaluated rodent composition, abundance, and antibody prevalence in wild rodents in three subtropical sites: primary forest, secondary forest, and crop fields.
View Article and Find Full Text PDFBilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer.
Med
December 2024
Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Article Synopsis
- * In the trial with 30 patients, the results showed a median progression-free survival of 4.1 months and an overall survival of 7.4 months, though the primary survival endpoint was not achieved.
- * Most patients tolerated the treatment well, with a notable 24-month survival rate of 23.3%, which was higher than previously reported for this combination.
Hepatopulmonary syndrome in biliary atresia children increased postoperative complications after liver transplantation.
Pediatr Neonatol
November 2024
Departments of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:
Background: Hepatopulmonary syndrome (HPS) is a complication in biliary atresia (BA) children following hepatoportoenterostomy. Liver transplantation (LT) was the definitive treatment of HPS. However, little was known about the risk factors between HPS and mortalities.
View Article and Find Full Text PDFHepatopulmonary syndrome secondary to metabolic associated fatty liver disease in childhood - novel treatment with growth hormone replacement therapy: a case report and systematic review of literature.
Front Endocrinol (Lausanne)
November 2024
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea.
Objective: Hepatopulmonary syndrome (HPS) is a rare complication of metabolic associated fatty liver disease (MAFLD) occurring subsequent to hypopituitarism, often developing after resection of hypothalamic or pituitary tumors. The aim of this study is to report an illustrative case of an HPS patient who was successfully treated with growth hormone replacement therapy, without liver transplantation which is conventionally regarded as the only treatment option. Additionally, we conducted a comprehensive review of published case reports of HPS in the pediatric population.
View Article and Find Full Text PDFHepatopulmonary syndrome associated with long-term use of ado-trastuzumab emtansine (T-DM1) for treatment of HER2-positive metastatic breast cancer - a case report and series.
Front Oncol
October 2024
Department of Oncology, Mayo Clinic, Rochester, MN, United States.
Article Synopsis
- ADCs in Cancer Therapy
- : Antibody-drug conjugates (ADCs), like ado-trastuzumab emtansine (T-DM1), are a significant breakthrough in cancer treatment, specifically for HER2-positive breast cancer, allowing targeted delivery of drugs to tumor cells while sparing normal tissue, but they can cause severe toxicity requiring monitoring.
- Hepatopulmonary Syndrome (HPS) Cases
- : A case series of four patients who received T-DM1 revealed they developed hepatopulmonary syndrome (HPS), which involves severe respiratory issues and is linked to long-term liver damage caused by the drug.
- Need for Awareness
- : The findings underscore the importance of recognizing
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!